[{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bacthera","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bacthera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bacthera \/ Seres Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bacthera \/ Seres Therapeutics"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danish Ministry of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Danish Ministry of Health","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Danish Ministry of Health"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radhoud University Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Radhoud University Medical","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Radhoud University Medical"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radboud University Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Radboud University Medical Centre","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Radboud University Medical Centre"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"MVA-BN Filo Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ GSK"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : CHIKV VLP is a vaccine candidate which is being investigated for immunization against chikungunya virus infection in individuals 12 years of age and older.

                          Product Name : PXVX0317

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 13, 2024

                          Lead Product(s) : PXVX0317

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : CHIKV VLP is a vaccine candidate which is being investigated for immunization against chikungunya virus infection in individuals 12 years of age and older.

                          Product Name : PXVX0317

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 17, 2024

                          Lead Product(s) : PXVX0317

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : Company has filed sBLA seeking approval for its new freeze-dried formulation of JYNNEOS® for prevention of smallpox and mpox disease in adults 18 years of age and older.

                          Product Name : Jynneos

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 31, 2024

                          Lead Product(s) : Smallpox And Monkeypox Vaccine, Live, Nonreplicating

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : CHIKV VLP is a vaccine candidate which is being investigated for immunization against chikungunya virus infection in individuals 12 years of age and older.

                          Product Name : PXVX0317

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 29, 2024

                          Lead Product(s) : PXVX0317

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : PXVX0317 (CHIKV VLP) vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%. It is being evaluated for chikungunya fever.

                          Product Name : PXVX0317

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 23, 2024

                          Lead Product(s) : PXVX0317

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : MVA-BN RSV is based on bavarian nordic’s proprietary vaccine platform technology, MVA-BN, and incorporates five distinct RSV antigens to stimulate a broad immune response against both RSV subtypes (A and B).

                          Product Name : MVA-BN RSV

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 04, 2023

                          Lead Product(s) : MVA-BN RSV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : ABNCoV2 is being developed as a universal booster to any other type of COVID-19 vaccine and has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection.

                          Product Name : ABNCoV2

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 31, 2023

                          Lead Product(s) : ABNCoV2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : MVA-BN RSV is based on bavarian nordic’s proprietary vaccine platform technology, MVA-BN, and incorporates five distinct RSV antigens to stimulate a broad immune response against both RSV subtypes (A and B).

                          Product Name : MVA-BN RSV

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 22, 2023

                          Lead Product(s) : MVA-BN RSV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : ABNCoV2 is being developed as a universal booster to any other type of COVID-19 vaccine and has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection.

                          Product Name : ABNCoV2

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 27, 2023

                          Lead Product(s) : ABNCoV2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : PXVX0317 (CHIKV VLP) vaccine candidate was well tolerated and induced a robust and durable serum neutralizing antibody immune response against the Chikungunya virus up to two years.

                          Product Name : PXVX0317

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 20, 2023

                          Lead Product(s) : PXVX0317

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank